GITNUX MARKETDATA REPORT 2024
Statistics About The Average Psa With Prostate Bone Metastasis
The average PSA level in patients with prostate cancer and bone metastasis is typically elevated above 100 ng/mL.
In this post, we will discuss key statistics related to prostate cancer bone metastasis, focusing on Prostate-specific antigen (PSA) levels and their implications for diagnosis and survival rates. With insights from recent studies published in JAMA Oncology, we will explore how PSA levels serve as strong predictors of bone metastasis and the challenges faced by individuals with advanced prostate cancer.
Statistic 1
"Men with metastatic prostate cancer had an average Prostate-specific antigen (PSA) level of 150 ng/ml at diagnosis, according to a study published in JAMA Oncology."
Statistic 2
"People surviving for 5 years from their prostate cancer diagnosis, with bone metastasis, is 28%."
Statistic 3
"A PSA increase of 2.0 ng/mL or higher than the PSA nadir (lowest point) is a strong predictor of bone metastasis in prostate cancer."
Statistic 4
"The average bone metastasis free survival is only 40% at 5 years for those men with a PSA level greater than 20 ng/mL at diagnosis."
Statistic 5
"Almost 80% of patients with metastatic castrate-resistant prostate cancer (mCRPC) have bone metastases."
Statistic 6
"49% of patients with prostate cancer bone metastasis show an increase in PSA levels."
Statistic 7
"85% of metastatic prostate cancer cases involve metastasis to bone."
Statistic 8
"Over 90% of men with advanced prostate cancer develop bone metastases."
Statistic 9
"The 10-year relative survival rate for localized prostate cancer that has spread to other parts of the body, like bones, is 28%."